Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06073574 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Enrollment target: estimated 150 to confirmed 160 · Primary completion date changed from estimate of Mar 2026 to Mar 13, 2026 · Study completion date changed from estimate of Apr 2026 to Mar 13, 2026v4 Show 3 more changesShow less
    • Enrollment target: estimated 150 to confirmed 160
    • Primary completion date changed from estimate of Mar 2026 to Mar 13, 2026
    • Study completion date changed from estimate of Apr 2026 to Mar 13, 2026
  2. 2 versions Re-verified since Oct 9, 2024, no change to tracked fieldsv2-v3
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).
Trial Details
NCT Number NCT06073574
Lead Sponsor Ionis Pharmaceuticals, Inc.
Collaborators: AstraZeneca
Conditions Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov